Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma

SIMPLE SUMMARY: Enfortumab vedotin, a targeted therapy for advanced urothelial carcinoma, has shown efficacy, especially in those treated with platinum-based chemotherapy and immune-checkpoint inhibitors. The EV-301 phase III trial reported enhanced overall survival and response rates than conventio...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawahara, Takashi, Hasizume, Akihito, Uemura, Koichi, Yamaguchi, Katsuya, Ito, Hiroki, Takeshima, Teppei, Hasumi, Hisashi, Teranishi, Jun-ichi, Ousaka, Kimito, Makiyama, Kazuhide, Uemura, Hiroji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486515/
https://www.ncbi.nlm.nih.gov/pubmed/37686503
http://dx.doi.org/10.3390/cancers15174227

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486515/
https://www.ncbi.nlm.nih.gov/pubmed/37686503
http://dx.doi.org/10.3390/cancers15174227

Ejemplares similares